Experimental cancer vaccines show promise in maintenance Specific cancers After I get back.
In a phase 1 clinical trial led by the UCLA Health Jonsson Comprehensive Cancer Center, researchers tested a vaccine (ELI-002 2P) in 25 patients treated for pancreatic and colorectal cancer.
According to a UCLA press release, all patients had surgery to remove the tumor, showing “minimal signs of residual disease” or DNA traces, indicating they were at a higher risk of recurrence.
Women defeat deadly brain tumors with clinical trial cell therapy: “Really amazing”
Over 80% Pancreatic cancer Patients experience recurrence of the disease after surgery, and according to studies, between 40% and 50%, this occurs within the first year.
for Colorectal cancerthe recurrence rate is 30% to 50%, and is most likely to occur within the first two years after surgery.
Mutations in the KRAS gene are responsible for half of colorectal cancer and more than 90% of pancreatic cancer. vaccineTargeting these mutations, these were given via a series of injections to activate the immune response of the lymph nodes.
A majority of patients (21 out of 25) produce “KRAS-specific T cells,” indicating a strong immune response. Those with a higher T-cell response showed longer, no recurrence rates compared to those with a lower response, the researchers found.
After experimental drug testing, fatal brain tumor tumors in humans disappear
In three colon cancer patients and three pancreatic cancer patients, the vaccine appeared to remove all disease biomarkers.
Among patients who showed the strongest Immune responsethe majority remained cancer-free almost 20 months after receiving the vaccine.
The findings were published in Nature Medicine.
“This is an exciting advancement for patients with KRAS-led cancer, particularly pancreatic cancer. Standard treatment Zev Wainberg, the first author of the study, Zev Wainberg, a medical professor at the school of medicine at UCLA, and a researcher at the UCLA Health Jonsson Comprehensive Cancer Center, said that Zev Wainberg, the first author of the study.
“It was observed that patients who developed a strong immune response to the vaccine remained disease-free and survived much longer than expected.”
Another finding shows that 67% of patients in the trial exhibit an immune response to “additional tumor-associated mutations,” and that vaccines can be used to suppress “wider antitumor activity.”
According to researchers, one of the advantages of the ELI-002 2P is that it is considered “off-the-fly”. This means it was mass produced. Standardized vaccine It does not need to be personalized for each individual patient.
“This study shows that the ELI-002 2P vaccine can safely and effectively train the immune system to recognize and fight cancer-driven mutations,” Waynberg said.
“It offers a promising approach to generating accurate and durable immune responses without the complexity or cost of a fully personalized vaccine.”
The team has already completed registration for participants Phase 2 study This tests ELI-002 7P, the next iteration of a vaccine targeting a “wideer set” of KRAS mutations, the release states.
Click here to sign up for our health newsletter
The study was sponsored and funded by Elicio Therapeutics, a Massachusetts company that developed the vaccine.
This was carried out in collaboration with the MD Anderson Cancer Center and the Memorial Sloan Kettering Cancer Center.
Dr. Mark Siegelsenior medical analyst at Fox News, was not involved in the study, but commented that targeted therapy is becoming an increasingly important tool in the fight against cancer.
“Soft tumors, especially pancreatic tumors, are difficult to treat because they are not the same mutagenic (which can induce or cause mutations), like hematologic malignancies (hematologic cancers) and melanomas. A target ready for immunotherapy“He told Fox News Digital.
Visit us for more health articles www.foxnews.com/health
“The new cancer vaccines from UCLA are extremely promising as a major tool against these cancers, which “program” the immune system targeting these mutations, and have been shown in natural studies to elicit strong clinical responses. ”
